

29 September 2025

ASX Announcement

Notice of Annual General Meeting and Closing Date for Director Nominations

Firebrick Pharma Limited (ASX: FRE) (**Company** or **Firebrick**) advises that the Company's Annual General Meeting (**AGM**) is scheduled to be convened at 11.00am (AEDT) on Wednesday, 26 November 2025.

The AGM will be held as a virtual meeting through an online meeting platform powered by Automatic, where Shareholders will be able to watch, listen, and vote online.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Wednesday, 8 October 2025. Any nominations must be received in writing at the Company's registered office by 5.00pm (AEDT).

The AGM materials will be produced and provided to shareholders in due course.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com